Search results
Results from the WOW.Com Content Network
[223] [224] In 1954, the stimulant methylphenidate (Ritalin, which was first produced in 1944) became available; it remains one of the most widely prescribed medications for ADHD. Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ...
ADHD prescription rates have historically been lower for women than men ... (an ADHD medication marketed under brand names like Ritalin and Concerta) than boys (55.8% vs. 69.7%, respectively ...
One in four U.S. adults suspects they may have ADHD and drugs are a first line of treatment for this condition. But what does research say about their impact on the brain and quality of life?
It will take time for public health researchers to gather, analyze and publish post-pandemic data, but the CDC reported a 344 percent increase in privately insured adult women who filled an ADHD ...
Guanfacine, sold under the brand name Tenex (immediate-release) and Intuniv (extended-release) among others, is an oral alpha-2a agonist medication used to treat attention deficit hyperactivity disorder (ADHD) and high blood pressure. [3] [10] Common side effects include sleepiness, constipation, and dry mouth. [10]
Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults. [1]Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.
Large, high quality research has found small differences in the brain between ADHD and non-ADHD patients. [1] [15] Jonathan Leo and David Cohen, critics who reject the characterization of ADHD as a disorder, contended in 2003 and 2004 that the controls for stimulant medication usage were inadequate in some lobar volumetric studies, which makes it impossible to determine whether ADHD itself or ...
Over just two years, between 2020-2022, the incidence of ADHD diagnoses in women ages 23 to 49 nearly doubled, contributing to an ongoing medication shortage in the United States.